Skip Navigation LinksHome > May/June 2010 - Volume 17 - Issue 3 > The effects of raloxifene on mammographic breast density: a...
Menopause:
doi: 10.1097/gme.0b013e3181c29e56
Review Articles

The effects of raloxifene on mammographic breast density: a review of clinical trials

Pearman, Leny MS, CNS1; Kagan, Risa MD, FACOG, CCD, NCMP2; Arsenault, Jody PhD1; Muram, David MD1

Collapse Box

Abstract

Objective: Breast density is an independent risk factor for the development of invasive breast cancer (BC). It has been hypothesized that because raloxifene (RLX) has been shown to reduce BC risk, its use will result in reduced breast density.

Methods: This article provides a review of seven clinical studies that examined the effects of RLX on breast density.

Results: Overall, RLX did not increase or decrease mammographic breast density. This article provides a review of the various methods used to determine breast density in these RLX studies and offers a potential explanation as to why the studies failed to show an effect on mammographic density.

Conclusions: Presently, no clinical recommendations can be made with regard to RLX and its effects on breast density. To determine the effect of RLX on breast density, larger studies need to be conducted in postmenopausal women with high breast density at baseline who are at high risk for BC, with a standardized method of breast density measurement.

©2010The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.